EU gives rivals Gilead and J&J’s leukemia drugs the thumbs up

Gilead Sciences, which received FDA approval for its new blood cancer drug Zydelig (idelalisib), has now been recommended for its use in Europe. But competitor Imbruvica from Johnson & Johnson, which got a head start in the US, has also received a nod from EU authorities. The Committee for Medicinal Products for Human Use said that it recommended both drugs for treatment of adults with chronic lymphocytic leukemia who have received at least one prior treatment, as well as a first-line treatment for patients with a specific genetic mutation that makes them unsuitable for chemo-immunotherapy.

Read the source article at Pharma News

About the Author

Leave a Reply